guest ::
| Home > Publications Database > Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. > print |
| Home > Publications Database > Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. > print |
| 001 | 162738 | ||
| 005 | 20250415100046.0 | ||
| 024 | 7 | _ | |a 10.1002/ana.26094 |2 doi |
| 024 | 7 | _ | |a pmid:33938021 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC8252519 |2 pmc |
| 024 | 7 | _ | |a 0364-5134 |2 ISSN |
| 024 | 7 | _ | |a 1531-8249 |2 ISSN |
| 024 | 7 | _ | |a altmetric:105201723 |2 altmetric |
| 037 | _ | _ | |a DZNE-2021-01395 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Lai, Dongbing |0 0000-0001-7803-580X |b 0 |
| 245 | _ | _ | |a Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. |
| 260 | _ | _ | |a Hoboken, NJ |c 2021 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1744637381_21650 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age-at-onset of Parkinson's disease.We performed the first genomewide association study of penetrance and age-at-onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non-cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age-at-onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age-at-onset in LRRK2 mutation carriers.A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E-08, beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co-immunoprecipitation analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant: p value = 1.1E-07; age-at-onset top variant: p value = 9.3E-07). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age-at-onset.This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of LRRK2 mutations. ANN NEUROL 2021;90:82-94. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to DataCite |
| 650 | _ | 7 | |a Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |0 EC 2.7.11.1 |2 NLM Chemicals |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Genetic Predisposition to Disease |2 MeSH |
| 650 | _ | 2 | |a Genome-Wide Association Study |2 MeSH |
| 650 | _ | 2 | |a Genotype |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Leucine-Rich Repeat Serine-Threonine Protein Kinase-2: genetics |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Mutation |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: genetics |2 MeSH |
| 650 | _ | 2 | |a Penetrance |2 MeSH |
| 700 | 1 | _ | |a Alipanahi, Babak |b 1 |
| 700 | 1 | _ | |a Fontanillas, Pierre |b 2 |
| 700 | 1 | _ | |a Schwantes-An, Tae-Hwi |b 3 |
| 700 | 1 | _ | |a Aasly, Jan |b 4 |
| 700 | 1 | _ | |a Alcalay, Roy N |b 5 |
| 700 | 1 | _ | |a Beecham, Gary W |b 6 |
| 700 | 1 | _ | |a Berg, Daniela |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Bressman, Susan |b 8 |
| 700 | 1 | _ | |a Brice, Alexis |b 9 |
| 700 | 1 | _ | |a Brockmann, Kathrin |0 P:(DE-2719)2811916 |b 10 |u dzne |
| 700 | 1 | _ | |a Clark, Lorraine |b 11 |
| 700 | 1 | _ | |a Cookson, Mark |b 12 |
| 700 | 1 | _ | |a Das, Sayantan |b 13 |
| 700 | 1 | _ | |a Van Deerlin, Vivianna |b 14 |
| 700 | 1 | _ | |a Follett, Jordan |b 15 |
| 700 | 1 | _ | |a Farrer, Matthew J |b 16 |
| 700 | 1 | _ | |a Trinh, Joanne |b 17 |
| 700 | 1 | _ | |a Gasser, Thomas |0 P:(DE-2719)2320009 |b 18 |u dzne |
| 700 | 1 | _ | |a Goldwurm, Stefano |b 19 |
| 700 | 1 | _ | |a Gustavsson, Emil |b 20 |
| 700 | 1 | _ | |a Klein, Christine |0 0000-0003-2102-3431 |b 21 |
| 700 | 1 | _ | |a Lang, Anthony E |b 22 |
| 700 | 1 | _ | |a Langston, J William |b 23 |
| 700 | 1 | _ | |a Latourelle, Jeanne |b 24 |
| 700 | 1 | _ | |a Lynch, Timothy |b 25 |
| 700 | 1 | _ | |a Marder, Karen |b 26 |
| 700 | 1 | _ | |a Marras, Connie |b 27 |
| 700 | 1 | _ | |a Martin, Eden R |b 28 |
| 700 | 1 | _ | |a McLean, Cory Y |b 29 |
| 700 | 1 | _ | |a Mejia-Santana, Helen |b 30 |
| 700 | 1 | _ | |a Molho, Eric |b 31 |
| 700 | 1 | _ | |a Myers, Richard H |b 32 |
| 700 | 1 | _ | |a Nuytemans, Karen |b 33 |
| 700 | 1 | _ | |a Ozelius, Laurie |b 34 |
| 700 | 1 | _ | |a Payami, Haydeh |b 35 |
| 700 | 1 | _ | |a Raymond, Deborah |b 36 |
| 700 | 1 | _ | |a Rogaeva, Ekaterina |b 37 |
| 700 | 1 | _ | |a Rogers, Michael P |b 38 |
| 700 | 1 | _ | |a Ross, Owen A |0 0000-0003-4813-756X |b 39 |
| 700 | 1 | _ | |a Samii, Ali |b 40 |
| 700 | 1 | _ | |a Saunders-Pullman, Rachel |b 41 |
| 700 | 1 | _ | |a Schüle, Birgitt |b 42 |
| 700 | 1 | _ | |a Schulte, Claudia |0 P:(DE-2719)9000366 |b 43 |u dzne |
| 700 | 1 | _ | |a Scott, William K |b 44 |
| 700 | 1 | _ | |a Tanner, Caroline |b 45 |
| 700 | 1 | _ | |a Tolosa, Eduardo |b 46 |
| 700 | 1 | _ | |a Tomkins, James E |b 47 |
| 700 | 1 | _ | |a Vilas, Dolores |b 48 |
| 700 | 1 | _ | |a Trojanowski, John Q |0 P:(DE-HGF)0 |b 49 |
| 700 | 1 | _ | |a Team, 23andMe Research |b 50 |e Collaboration Author |
| 700 | 1 | _ | |a Uitti, Ryan |b 51 |
| 700 | 1 | _ | |a Vance, Jeffery M |b 52 |
| 700 | 1 | _ | |a Visanji, Naomi P |0 0000-0001-5968-7845 |b 53 |
| 700 | 1 | _ | |a Wszolek, Zbigniew K |b 54 |
| 700 | 1 | _ | |a Zabetian, Cyrus P |0 0000-0002-7739-4306 |b 55 |
| 700 | 1 | _ | |a Mirelman, Anat |0 0000-0002-1520-2292 |b 56 |
| 700 | 1 | _ | |a Giladi, Nir |b 57 |
| 700 | 1 | _ | |a Orr Urtreger, Avi |b 58 |
| 700 | 1 | _ | |a Cannon, Paul |b 59 |
| 700 | 1 | _ | |a Fiske, Brian |b 60 |
| 700 | 1 | _ | |a Foroud, Tatiana |b 61 |
| 773 | _ | _ | |a 10.1002/ana.26094 |g Vol. 90, no. 1, p. 76 - 88 |0 PERI:(DE-600)2037912-2 |n 1 |p 76 - 88 |t Annals of neurology |v 90 |y 2021 |x 1531-8249 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/162738/files/DZNE-2021-01395.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/162738/files/DZNE-2021-01395.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:162738 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2811916 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 18 |6 P:(DE-2719)2320009 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 43 |6 P:(DE-2719)9000366 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-30 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ANN NEUROL : 2021 |d 2022-11-30 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b ANN NEUROL : 2021 |d 2022-11-30 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-02-03 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-03 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0 |0 LIC:(DE-HGF)CCBYNC4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-30 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-30 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-30 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-30 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser |l Parkinson Genetics |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)5000055 |k AG Berg |l Parkinson's Disease Genetics |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a I:(DE-2719)5000055 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|